Tekla Life Sciences Investors

NYSE:HQL

Asset Management

Financial Services
$19.27 +0.62%

+$0.11 today

Market cap
$585.96M
Beta
0.73
P/E (TTM)
2.8
EPS (TTM)
$6.52
Dividend yield
11.35%
52W Low $12.34High $18.46

Volume 0.12M

Average 0.11M

HQL Inventory

Cash effect of the change in inventory; building inventory consumes cash.

Tekla Life Sciences InvestorsNYSE: HQL

Inventory · Q2 FY2026 · quarter ended Mar 2026

Inventory outflow grows to $0

Q2 FY2026 inventory was $0, compared with $0 a year earlier.

Context

  • Inventory amounted to 0.0% of revenue in FY2025.
  • Inventory increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearSep 2025
$0— YoY
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Inventory vs competitors

How HQL compares with its peers on the latest reported figures

  • HQL's FY2025 inventory of $0 is the largest of the 10 companies compared; the peer median is $0.
  • Inventory amounts to 0.0% of revenue for HQL, versus a peer median of 0.0%.
HQL Competitors Peer median
Inventory for HQL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HQLTekla Life Sciences InvestorsFY2025$0 ——0.0%
GAINGladstone Investment CorporationLTM Mar 2026$0 ——0.0%
ECCEagle Point Credit Company Inc.LTM Dec 2025$0 ——0.0%
GLADGladstone Capital CorporationLTM Mar 2026$0 ——0.0%
CCAPCrescent Capital BDC, Inc.LTM Mar 2026$0 ——0.0%
SORSource Capital, Inc.FY2024$0 ——0.0%
MCIBarings Corporate InvestorsLTM Jun 2025$0 ——0.0%
CIONCION Investment CorporationLTM Mar 2026$0 ——0.0%
TCPCBlackRock TCP Capital Corp.LTM Mar 2026$0 ——0.0%
PNNTPennantPark Investment CorporationLTM Mar 2026$0 ——0.0%
Peer median (excluding HQL) $0——0.0%

Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2020
Sep 2020
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2025
Sep 2025
Net Income123.05K64.53K(104.6K)22.35M85.59M
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital0000(203.41K)
Accounts Receivables000059.23K
Inventory00000
Accounts Payables00000
Other Working Capital0000(262.64K)
Other Non-Cash Items(123.05K)(64.53K)104.6K(22.35M)(87.71M)
Operating Cash Flow0000(2.32M)
Capital Expenditures0000(5)
Acquisitions (Net)00000
Purchases of Investments0000(314.13M)
Sales of Investments0000339.34M
Other Investing Activities00000
Investing Cash Flow000025.21M
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased00000
Dividends Paid0000(31.63M)
Other Financing Activities00000
Financing Cash Flow0000(31.63M)
Effect of Forex Changes00008.81M
Net Change in Cash0990(545)3275.54K
Free Cash Flow0000(2.32M)

Tekla Life Sciences Investors

NYSE:HQL

Intrinsic Alpha fair value

Locked

Current Price

$19.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.